Pulmonx Corp SEC Filings

Pulmonx Corp President and CEO Glendon E. French III reported open-market sales of 67,813 shares of common stock. The sales occurred on March 2, 2026 at $1.43 per share in three transactions. Footnotes state the shares were sold to cover tax withholding obligations tied to vesting of restricted stock units granted in 2022 and 2023. After these sales, he directly held 1,409,511 shares, with an additional 742,998 shares held indirectly by a family trust.

Pulmonx Corp reported insider transactions by its Chief Commercial Officer, Geoffrey Beran. On March 2, 2026, he sold a total of 7,732 shares of common stock at $1.43 per share in open-market sales to cover tax withholding obligations tied to vesting restricted stock units granted in 2022, 2023, 2024, and 2025.

On the same date, he received a grant of 100,000 restricted stock units, payable solely in Pulmonx common stock, which vest in equal quarterly installments over four years from March 2, 2026. Following these transactions, his direct holdings increased to 465,734 shares of common stock.

Pulmonx Corp reported insider transactions by its Chief Commercial Officer, Geoffrey Beran. On March 2, 2026, he sold a total of 7,732 shares of common stock at $1.43 per share in open-market sales to cover tax withholding obligations tied to vesting restricted stock units granted in 2022, 2023, 2024, and 2025.

On the same date, he received a grant of 100,000 restricted stock units, payable solely in Pulmonx common stock, which vest in equal quarterly installments over four years from March 2, 2026. Following these transactions, his direct holdings increased to 465,734 shares of common stock.

Pulmonx Corp’s general counsel, David Aaron Lehman, reported multiple insider transactions in Pulmonx common stock. On March 2, 2026, he sold a total of 12,237 shares in open‑market transactions at $1.43 per share. Footnotes state these sales were made to cover tax withholding obligations tied to the vesting of restricted stock units (RSUs) granted between March 1, 2022 and March 3, 2025, indicating they were not discretionary portfolio sales. On the same date, he received a grant of 150,000 RSUs payable solely in common stock, vesting in equal quarterly installments over four years from March 2, 2026. Following these transactions, his directly held Pulmonx shares increased to 390,755.

Pulmonx Corp’s general counsel, David Aaron Lehman, reported multiple insider transactions in Pulmonx common stock. On March 2, 2026, he sold a total of 12,237 shares in open‑market transactions at $1.43 per share. Footnotes state these sales were made to cover tax withholding obligations tied to the vesting of restricted stock units (RSUs) granted between March 1, 2022 and March 3, 2025, indicating they were not discretionary portfolio sales. On the same date, he received a grant of 150,000 RSUs payable solely in common stock, vesting in equal quarterly installments over four years from March 2, 2026. Following these transactions, his directly held Pulmonx shares increased to 390,755.

Pulmonx Corporation reported mixed fourth quarter and full-year 2025 results while issuing cautious 2026 guidance. Full-year 2025 revenue reached $90.5 million, up 8% from 2024, driven by 23% international growth, while U.S. revenue grew 1%. Fourth quarter revenue was $22.6 million, down 5% year over year, as U.S. sales declined 11% but international revenue rose 8%.

Profitability metrics improved modestly. Full-year gross profit was $67.1 million with a 74% gross margin, and fourth quarter gross margin increased to 78%. The company narrowed its net loss to $54.0 million for 2025, or $1.33 per share, from a $56.4 million loss in 2024, and reduced its adjusted EBITDA loss to $30.6 million.

Pulmonx ended 2025 with $69.8 million in cash, cash equivalents, and marketable securities, down about $32 million over the year. It refinanced its debt with a new 5-year interest-only credit facility providing up to $60 million and extending maturity to 2031, and executed a cost restructuring to lower operating expenses. For 2026, the company guides revenue to $90–$92 million, gross margin around 75%, operating expenses of $113–$115 million (including about $21 million of stock-based compensation), and expects cash and investments to decline by roughly $23 million, assuming no further credit facility drawdowns.

Pulmonx Corporation reported mixed fourth quarter and full-year 2025 results while issuing cautious 2026 guidance. Full-year 2025 revenue reached $90.5 million, up 8% from 2024, driven by 23% international growth, while U.S. revenue grew 1%. Fourth quarter revenue was $22.6 million, down 5% year over year, as U.S. sales declined 11% but international revenue rose 8%.

Profitability metrics improved modestly. Full-year gross profit was $67.1 million with a 74% gross margin, and fourth quarter gross margin increased to 78%. The company narrowed its net loss to $54.0 million for 2025, or $1.33 per share, from a $56.4 million loss in 2024, and reduced its adjusted EBITDA loss to $30.6 million.

Pulmonx ended 2025 with $69.8 million in cash, cash equivalents, and marketable securities, down about $32 million over the year. It refinanced its debt with a new 5-year interest-only credit facility providing up to $60 million and extending maturity to 2031, and executed a cost restructuring to lower operating expenses. For 2026, the company guides revenue to $90–$92 million, gross margin around 75%, operating expenses of $113–$115 million (including about $21 million of stock-based compensation), and expects cash and investments to decline by roughly $23 million, assuming no further credit facility drawdowns.

A shareholder of NASDAQ-listed LUNG, identified as Steven Williamson, has filed a Rule 144 notice to sell 48,892 shares of common stock through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of 95,339.40 for these shares, with 41,247,034 shares outstanding for the issuer. The planned sale is to be executed on or about 01/22/2026 on the NASDAQ exchange.

The notice also reports that during the past three months, the same seller disposed of additional common shares, including 15,892 shares on 01/15/2026 for gross proceeds of 31,038.67 and 31,082 shares on 01/14/2026 for gross proceeds of 62,073.62. The securities to be sold in this notice were acquired as restricted stock directly from the issuer in several transactions during 2025.

Steven Williamson has filed a notice of proposed sale under Rule 144 to sell 15,892 shares of common stock of LUNG through Morgan Stanley Smith Barney LLC at an aggregate market value of $31,038.67, with the shares listed on NASDAQ. The filing notes that 41,247,034 shares of this class were outstanding, providing context for the planned sale size.

The shares to be sold come from restricted stock acquired from the issuer on March 3, 2025 (11,796 shares) and June 1, 2025 (4,096 shares), both marked as not involving special payment arrangements. Over the prior three months, Williamson sold 31,082 common shares for gross proceeds of $62,073.62. By signing the notice, the seller represents that he is not aware of undisclosed material adverse information about LUNG’s current or prospective operations.

A shareholder of LUNG has filed a notice of proposed sale under Rule 144 to sell 31,082 common shares through Morgan Stanley Smith Barney LLC. The filing lists an aggregate market value of 62,073.62 for these shares, with an approximate sale date of January 14, 2026 on NASDAQ. The notice also shows that 41,247,034 common shares are outstanding and that the shares to be sold were acquired via restricted stock, open market purchases, and an employee stock purchase plan.

Pulmonx Corp reported new equity awards to its Chief Operating Officer and Chief Financial Officer on December 1, 2025. The executive received 1,200,000 Restricted Stock Units that are payable in common stock. According to the terms, 25% of these units vest one year after the grant date, with the remaining balance vesting in equal quarterly installments over the following three years.

The executive also received 400,000 Performance Stock Units, each tied to one share of common stock. These units vest only if two conditions are met: the company’s stock reaches a specified price per share and time-based milestones are satisfied, with 33% vesting one year after the grant date and the rest in eight equal quarterly installments through December 1, 2028. Both awards are shown at a price of $0, reflecting that they are equity incentives rather than open-market purchases.

Pulmonx Corporation has filed an amended shelf registration statement on Form S-3 that allows it to offer and sell up to an aggregate of $200,000,000 of securities over time. The company may issue common stock, preferred stock, debt securities and warrants, either individually or in combination, and may also issue common or preferred stock or debt upon conversion or exercise of these instruments. Specific terms such as pricing, maturity, interest or dividend features, and underwriting arrangements will be set in future prospectus supplements for each offering. Pulmonx states that, unless otherwise described in a supplement, net proceeds will be used for working capital, research and development, capital expenditures and other general corporate purposes. The filing highlights that investing in its securities involves a high degree of risk and directs investors to detailed risk factors in its Annual and Quarterly Reports.